ABVC BioPharmaABVC +6.25%17 PB Ratio is 3.56 as of Jun. 26, 2026, which is 60% below its 10-year median of 8.81. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, ABVC BioPharma ranks worse than 58.12% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), ABVC BioPharma's share price is $1.53. ABVC BioPharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.43. Hence, ABVC BioPharma's PB Ratio of today is 3.56.
The historical rank and industry rank for ABVC BioPharma's PB Ratio or its related term are showing as below:
ABVC'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 8.81 Max: 274.18
Current: 3.56
During the past 13 years, ABVC BioPharma's highest PB Ratio was 274.18. The lowest was 0.43. And the median was 8.81.
ABVC's PB Ratio is ranked worse than 58.12% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ABVC: 3.56
During the past 12 months, ABVC BioPharma's average Book Value Per Share Growth Rate was 16.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -21.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ABVC BioPharma was 82.00% per year. The lowest was -68.80% per year. And the median was 0.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ABVC BioPharma PB Ratio Related Terms
ABVC BioPharma PB Ratio Historical Data
* Premium members only.
The historical data trend for ABVC BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ABVC BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ABVC BioPharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ABVC BioPharma (ABVC) has a PB Ratio of 3.56 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ABVC BioPharma and its competitors. This is 60% below median its historical median of 8.81. Over the past decade, ABVC BioPharma's PB Ratio has ranged from 0.43 to 274.18. According to the industry distribution chart, ABVC BioPharma ranks #716 out of 1232 companies in the Biotechnology industry, placing it in the top 58.1%.
Is ABVC BioPharma's PB Ratio too high?
ABVC BioPharma's current PB Ratio of 3.56 is 60% below median its 10-year median of 8.81. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 274.18. The Biotechnology industry median PB Ratio is 2.80. ABVC BioPharma's value of 3.56 is 27.1% above this industry median. Based on the distribution chart, ABVC BioPharma ranks #716 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's PB Ratio compare to GRDX and INMB?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #716 out of 1232 companies for PB Ratio. This places ABVC BioPharma in the lower half of its industry. The industry median PB Ratio is 2.80. ABVC BioPharma's value of 3.56 is 27.1% above this benchmark. Historically, ABVC BioPharma's own PB Ratio has ranged from 0.43 to 274.18 over the past decade. While the company's 10-year median is 8.81 vs. the industry median of 2.80, ABVC BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABVC BioPharma's current PB Ratio of 3.56 is 27.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ABVC BioPharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current PB Ratio is 3.56, which is 60% below median its own 10-year median of 8.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.53 — trading 75.9% above its estimated fair value. The current PB Ratio is 3.56, which is 60% below median its 10-year median of 8.81 and 27.1% above the Biotechnology industry median of 2.80. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current PB Ratio is 3.56 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $1.53 is trading 75.9% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
PB Ratio: 3.56 (60% below median its 10-year median of 8.81)
GF Value™: $0.87 vs. price of $1.53 (75.9% above fair value)
Industry Position: 27.1% above the Biotechnology median (#716 of 1232)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
